NCT03001622View on ClinicalTrials.gov

Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions

Hidradenitis Suppurativa

Interventions

BIOLOGICAL

IFX-1

chimeric, monoclonal antibody

Trial Locations (1)

12462

ATTIKON University Hospital, Athens

Sponsors

Lead Sponsor

All Listed Sponsors

lead

InflaRx GmbH

INDUSTRY

NCT03001622 - Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter